How Are PDL BioPharma Inc(NASDAQ:PDLI), Nektar Therapeutics(NASDAQ:NKTR), and Eli Lilly and Co(NYSE:LLY) Faring In The Pharmaceutical Sector?

Posted by Saimoon October 21, 2014 0 Comment 721 views


New York, NY – GDP INSIDER  –  10/21/2014.

This article discusses three pharmaceutical companies: PDL BioPharma Inc(NASDAQ:PDLI), Nektar Therapeutics(NASDAQ:NKTR), and Eli Lilly and Co(NYSE:LLY)

PDL BioPharma Inc(NASDAQ:PDLI) is a Nevada-based biotechnology company that manages a portfolio of patients and royalty assets. On Oct. 17th, Pomerantz LLP announced that it had filed a class action lawsuit against the company and certain officers. The lawsuit is on behalf of individuals who purchased securities in the company between Nov. 6th, 2013 and Sept. 16th, 2014. As with many class action lawsuits, it seeks to recover damages from alleged federal securities laws violations.

Is PDL A Potential Midday Trade Candidate? View Our Free PDLI Analysis.

Nektar Therapeutics(NASDAQ:NKTR) is a clinical-stage biopharmaceutical company that develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. The company’s drug candidates include naloxegol, an opioid antagonist and BAY41-6551, which would be used to treat gram-negative pneumonias. The California-based company has a market capitalization of over $1.58 billion and 127.3 million tradeable shares. Nektar Therapeutics has traded within a range of $8.87 to $15.34 over the past 52 weeks.

How Should You Approach A Potential Nektar Therapeutics Investment? Take A Look At Our Free NKTR Analysis.

Eli Lilly and Co(NYSE:LLY) had a bid price of $62.50 x 100 and an offer price of $65.00 x 400 on Oct. 21st, 2014, figures which suggest the company’s trading value may soon fluctuate. However, the company only had a trading volume of 2.9 million on Oct. 20th, a figure which is 0.97 million lower than its three month average volume of 3.87 million. That figure could spike on Oct. 23rd, when the company will be releasing its next earnings report.

Should You Invest In Eli Lilly Before The Company Releases Its Financial Results Report? View Our Free LLY Analysis.

About HotStockGains

HotStockGains.com provides investors and traders with trading strategies via text message and email. To obtain text message stock alerts service text the word BREAKOUT to 555888 from your cell phone.

Additionally, HotStockGains free newsletter provides market insight, tips, and trading strategies on NYSE, NASDAQ, OTCBB and PINK stocks.

Disclosure:  HotStockGains is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Always seek help from a professional financial advisor (I am not one). Please visit http://hotstockgains.com/disclaimer/ for complete risks and disclosures.


Write Your Comment